logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Hong Kong stocks soared after China Renewable Energy Investment (00987.HK) reported a profit increase of over 20%, with an expected mid-term comprehensive net profit growth of more than 1.9 times.

date
20/08/2025
According to the Wise Finance app, Chinese Renewable Energy Investment (00987.HK) surged over 20% after reporting a profit. As of the time of writing, it has risen by 17.99% to 0.164 Hong Kong dollars, with a trading volume of 4.5776 million Hong Kong dollars.
Latest
3 m ago
On August 20, Novartis announced that its innovative product Nuralda (Arquerant hydrochloride tablets) has been approved by the National Medical Products Administration for the reduction of proteinuria in adult patients with primary IgA nephropathy who are at risk of rapid disease progression. It is reported that Nuralda is the first non-immunological therapy approved in China for the treatment of IgA nephropathy. It is also the first and currently the only highly selective endothelin A (ETA) receptor antagonist for this indication in the country.
3 m ago
Novartis' innovative drug Nolasiban has been approved for the treatment of IgA nephropathy in China.
3 m ago
Britain's inflation accelerates and hits an 18-month high, central bank may reconsider interest rate cuts
4 m ago
The stock price of Cambrian has once again broken through 1,000 yuan, making it the second stock above 1,000 yuan in the current market.
5 m ago
Hongtian stock hit the daily limit up.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.